HB1062 mandates coverage for biomarker testing in Washington state starting January 1, 2026.

HB1062 requires health carriers to cover biomarker testing for diagnosis, treatment, management, or monitoring of diseases or conditions, provided the test is supported by medical and scientific evidence. The bill mandates coverage for biomarker testing in health plans issued or renewed on or after January 1, 2026. Biomarker testing must be supported by evidence such as labeled indications for tests approved by the United States Food and Drug Administration, Centers for Medicare and Medicaid Services national coverage determinations, nationally recognized clinical practice guidelines, or.

HB1062 mandates coverage for biomarker testing in Washington state starting January 1, 2026.

HB1062 requires health carriers to cover biomarker testing for diagnosis, treatment, management, or monitoring of diseases or conditions, provided the test is supported by medical and scientific evidence. The bill mandates coverage for biomarker testing in health plans issued or renewed on or after January 1, 2026. Biomarker testing must be supported by evidence such as labeled indications for tests approved by the United States Food and Drug Administration, Centers for Medicare and Medicaid Services national coverage determinations, nationally recognized clinical practice guidelines, or.